ヒドロキシクロロキンとクロロキン市場：タイプ、用途、地域範囲と予測

ヒドロキシクロロキンとクロロキンの市場評価～2026～2032年

マラリアは、特に発展途上国において、公衆衛生上の重大な懸念であり続けています。ヒドロキシクロロキンはマラリアの治療として確立されており、マラリア患者数の増加が市場の成長を促進する可能性が高いです。さらに、これらの薬剤はループスや関節リウマチのような自己免疫疾患の治療にも使用されており、これらの疾患も有病率の増加を目の当たりにしています。市場規模は2024年に39億5,000万米ドルを突破し、2032年には1兆1,204億1,000万米ドルの評価額に達します。

世界人口の高齢化が進み、高齢者は感染症にかかりやすくなっています。このため、ヒドロキシクロロキンのような抗マラリア薬の需要が高まり、市場拡大に寄与する可能性が高いです。開発途上諸国がヘルスケアへのアクセスと経済的負担の軽減に努める中、ヒドロキシクロロキンのような費用対効果の高い抗マラリア薬への需要が高まると予想されます。市場は2026～2032年までCAGR 102.57％で成長します。

ヒドロキシクロロキンとクロロキン市場定義/概要

ヒドロキシクロロキンとクロロキン市場は、マラリア、関節リウマチやループスを含む自己免疫疾患、場合によってはCOVID-19のようなウイルス感染症の治療に主に使用される、これら2つの薬剤を中心とした世界の医薬品と治療状況を指します。ヒドロキシクロロキンとクロロキンは、免疫調節作用と抗寄生虫作用を持つ4-アミノキノリン化合物です。市場には、様々な地域やヘルスケアシステムにおけるこれらの医薬品の製造、流通、使用が含まれます。

近年、ヒドロキシクロロキンとクロロキン市場は、特にCOVID-19パンデミックのような健康問題の高まりに反応して、大きな変動と注目を経験しています。ヒドロキシクロロキンとクロロキンの有効性については、臨床検査の結果が一致せず、意見が分かれているにもかかわらず、パンデミックの初期には需要が急増しました。医薬品の生産、規制当局の承認、臨床検査、公衆衛生施策はすべて、ヒドロキシクロロキンとクロロキンの世界の入手可能性、価格、使用に影響を与えます。

マラリアと自己免疫疾患の有病率の増加と高齢者の増加がヒドロキシクロロキンとクロロキン市場の成長をどのように促進しているか？

新興諸国ではマラリアの脅威が続いており、これらの医薬品、特に確立された治療法であるヒドロキシクロロキンの需要が高まっています。マラリア患者の世界の増加に伴い、ヘルスケアシステムが罹患者の治療ニーズを満たすべく取り組んでいることから、市場は成長する可能性が高いです。さらに、ループスや関節リウマチのような自己免疫疾患の有病率の増加も、この需要に寄与しています。これらの慢性疾患は世界的にますます一般的になっており、疾患管理プロトコルにおいてヒドロキシクロロキンやクロロキンの継続的な使用が必要となっています。もう一つの重要な要因は、世界人口の高齢化に伴う人口動態の変化です。高齢者は病気、特にマラリアにかかりやすく、ヒドロキシクロロキンのような抗マラリア薬の需要が高まると予想されます。このような人口動向は、高齢化に伴うヘルスケア需要を満たすために十分な医薬品供給を確保することの重要性を強調しています。

また、COVID-19治療におけるヒドロキシクロロキンの使用が期待される一方で、商業的な関心も依然として高いです。この関心は研究開発への投資を促し、実績のある用途に加え、ウイルス感染症に対する薬剤の有効性を調査することを目的としています。世界各国の政府によるマラリア対策への投資拡大も、抗マラリア薬へのアクセス拡大による市場拡大を後押ししています。このような積極的な関与により、マラリアが発生しやすい地域でのヒドロキシクロロキンやクロロキンの供給が増加し、市場の成長が促進されます。

さらに、ヘルスケアへのアクセスや経済的な余裕が大きな問題となっている開発途上国では、低価格の抗マラリア薬に対する需要が高まっています。市場の反応としては、費用対効果の高い製剤の製造や薬剤の生物学的利用能の向上が試みられており、これによってより効率的な代替治療が可能になり、将来の市場成長の原動力となる可能性があります。さらに、ヒドロキシクロロキンやクロロキンは、マラリアや自己免疫疾患以外の疾患の治療にも有用である可能性があるなど、新たな用途の研究が続けられており、市場の多様化の可能性が広がっています。このような新たな治療ルートの調査は、医薬品イノベーションの環境の変化と、それが市場力学に与えうる影響を強調するものです。

狼瘡や関節リウマチのような自己免疫疾患に対する一般市民の意識の高まりは、早期診断と治療開始につながり、これらの疾患を管理するためのヒドロキシクロロキンの使用を増加させると予測されます。このような患者やヘルスケア提供者の意識の高まりは、臨床現場におけるこれらの薬剤の幅広い受容と使用を促進することにより、市場に有益な影響を与えると予想されます。

ヒドロキシクロロキンやクロロキンの限られた臨床的有効性とともに、安全性の懸念や副作用はどのように関係しているのでしょうか？

ヒドロキシクロロキンとクロロキンは、胃腸障害や最も重大な心臓リズム障害の可能性など、さまざまな副作用に関連しています。これらの安全性リスクは、特に管理された環境以外で使用された場合や十分なモニタリングなしに使用された場合、医療従事者が薬剤を配合することや患者が一貫して薬剤を使用することを阻害する可能性があります。当初の関心にもかかわらず、大規模臨床検査の結果が一貫していないため、ヒドロキシクロロキンのCOVID-19治療としての有効性は不明です。このように明確な証拠がないため、パンデミック管理への応用拡大への熱意が抑えられ、市場成長の可能性が制限されています。

安全性への懸念から、FDAなどの規制機関は、認められた適応症や臨床検査以外でのヒドロキシクロロキンの使用を制限しています。このような厳しい規制手続きは配合を複雑にし、適応外使用を制限する可能性があるため、市場の成長を阻害します。新規抗マラリア薬や自己免疫疾患に対する他の治療が出現するにつれ、ヒドロキシクロロキンやクロロキンは厳しい競合に直面します。これらの代替薬がより優れた有効性プロファイルやより少ない副作用を持つ場合、患者の嗜好を揺るがし、これらの既存療法の市場シェアを低下させる可能性があります。

世界のサプライチェーンの混乱や原料不足により、ヒドロキシクロロキンやクロロキンが供給不足に陥ることもある可能性があります。こうしたサプライチェーンの欠陥は、市場の安定性を危うくし、重要な医薬品への患者のアクセスを制限する可能性があります。蚊の駆除や防虫加工を施した蚊帳などの予防対策を優先する公衆衛生の取り組みは、マラリア感染の減少に効果的です。このような予防対策が成功すれば、ヒドロキシクロロキンを含む抗マラリア薬の総需要が長期的に減少する可能性があります。

薬剤耐性マラリア株の出現と蔓延は、ヒドロキシクロロキンやクロロキンの有効性に対する大きな脅威となります。耐性菌の増加は、マラリア治療における薬剤の有用性を低下させ、市場需要を減少させ、代替治療技術を強制する可能性があります。安全性研究や規制の精査が進展するにつれ、ヒドロキシクロロキンやクロロキンはより多くの制限やガイドラインの修正に直面する可能性があります。規制の枠組みの変化は、配合プラクティスや市場参入条件を変えることで、市場力学に影響を与える可能性があります。

目次

第1章 世界のヒドロキシクロロキンとクロロキン市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 ヒドロキシクロロキンとクロロキンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ヒドロキシクロロキンとクロロキンの世界市場：タイプ別

• 概要
• 経口錠剤
• 注射剤

第6章 ヒドロキシクロロキンとクロロキンの世界市場：用途別

• 概要
• COVID-19
• 若年性特発性関節炎
• 関節リウマチ
• マラリア
• その他

第7章 ヒドロキシクロロキンとクロロキンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のヒドロキシクロロキンとクロロキン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Ipca Laboratories
• Zydus Cadila
• Sanofi S.A.
• McW Healthcare
• Macleods Pharmaceuticals Ltd
• Cipla Limited
• Lupin Limited
• Mylan N.V.
• Abbott India Ltd

第10章 付録

• 関連調査

Hydroxychloroquine And Chloroquine Market Valuation - 2026-2032

Malaria continues to be a significant public health concern, particularly in developing countries. Hydroxychloroquine is a well-established treatment for malaria, and the rising number of malaria cases is likely to propel market growth. Additionally, these drugs are used in treating autoimmune diseases like lupus and rheumatoid arthritis, which are also witnessing an increase in prevalence. The market size growth to surpass USD 3.95 Billion in 2024, to reach a valuation of USD 1120.41 Billion by 2032

The global population is aging, and older adults are more susceptible to infections. This is likely to heighten the demand for antimalarial drugs like hydroxychloroquine, thereby contributing to market expansion. As developing countries strive to improve healthcare access and affordability, the demand for cost-effective antimalarial drugs like hydroxychloroquine is expected to rise. The market is to grow at a CAGR of 102.57 % from 2026 to 2032

Hydroxychloroquine And Chloroquine Market: Definition/ Overview

The Hydroxychloroquine and Chloroquine market refers to the global pharmaceutical and therapeutic landscape centered on these two medications, largely used to treat malaria, autoimmune illnesses including rheumatoid arthritis and lupus, and possibly viral infections like COVID-19. Hydroxychloroquine and chloroquine are 4-aminoquinoline compounds with immunomodulatory and antiparasitic effects. The market includes the manufacturing, distributing, and using these medications in various areas and healthcare systems.

In recent years, the Hydroxychloroquine and Chloroquine markets have experienced significant volatility and attention, particularly in reaction to rising health problems like as the COVID-19 pandemic. Despite ongoing disagreements and conflicting clinical trial results on their efficacy for this specific purpose, demand for these medications skyrocketed during the early phases of the epidemic. Pharmaceutical production, regulatory approvals, clinical trials, and public health policies all impact the global availability, pricing, and use of hydroxychloroquine and chloroquine.

How Do the Increasing Prevalence of Malaria and Autoimmune Diseases, along with the Growing Geriatric Population, are Driving Growth of the Hydroxychloroquine and Chloroquine Market?

The ongoing threat of malaria in developing countries fuels demand for these medications, particularly hydroxychloroquine, a well-established therapy. With an increase in malaria cases worldwide, the market is likely to grow as healthcare systems work to satisfy the treatment needs of affected people. Furthermore, the increasing prevalence of autoimmune illnesses like lupus and rheumatoid arthritis contributes to this demand. These chronic illnesses are growing increasingly common worldwide, necessitating the ongoing use of hydroxychloroquine and chloroquine in disease management protocols. Another important factor is the demographic change toward an older global population. Older persons are more vulnerable to diseases, particularly malaria, which is expected to raise the demand for antimalarial medications such as Hydroxychloroquine. This demographic trend emphasizes the significance of ensuring an adequate medicine supply to fulfill the healthcare demands associated with aging.

Also, the prospective use of Hydroxychloroquine in COVID-19 treatment, while still being commercial interest. This interest has prompted investment in research and development, with the goal of investigating the drug's efficacy against viral infections in addition to its proven applications. Governments' increased investment in malaria control initiatives around the world helps to drive market expansion by assuring greater access to antimalarial medications. This proactive involvement increases the supply of hydroxychloroquine and chloroquine in malaria-prone areas, driving market growth.

Furthermore, there is an increasing demand for low-cost antimalarial medications in developing nations where healthcare access and affordability are significant concerns. The market reaction includes attempts to produce cost-effective formulations and improve drug bioavailability, which could lead to more efficient treatment alternatives and fuel future market growth. Furthermore, continuing research into new applications for hydroxychloroquine and chloroquine, such as their potential utility in treating ailments other than malaria and autoimmune diseases, offers exciting chances for market diversification. This investigation of new therapeutic routes emphasizes the changing environment of pharmaceutical innovation and its possible impact on market dynamics.

Increasing public awareness of autoimmune disorders such as lupus and rheumatoid arthritis is predicted to lead to earlier diagnosis and treatment initiation, increasing the use of Hydroxychloroquine to manage these conditions. This increased awareness among patients and healthcare providers is anticipated to have a beneficial impact on the market by encouraging broader acceptance and use of these medications in clinical practice.

How Do Safety Concerns and Adverse Effects, Along with Limited Clinical Efficacy for

Hydroxychloroquine and chloroquine have been linked to a variety of adverse effects, including gastrointestinal difficulties and, most significantly, possible heart rhythm disruptions. These safety risks, especially when used outside of controlled settings or without sufficient monitoring, can inhibit healthcare practitioners from prescribing medications and patients from using them consistently. Despite initial interest, hydroxychloroquine's efficacy as a COVID-19 treatment is unknown due to inconsistent results from large-scale clinical trials. This lack of clear evidence has tempered enthusiasm for its expanded application in pandemic management, restricting market growth potential.

Due to safety concerns, regulatory bodies such as the FDA have restricted the use of hydroxychloroquine outside of recognized indications or clinical trials. These severe regulatory procedures may complicate prescribing practices and limit off-label use, thereby impeding market growth. As novel antimalarial medications and other therapies for autoimmune illnesses emerge, hydroxychloroquine and chloroquine face stiff competition. If these alternatives have better efficacy profiles or fewer side effects, they may sway patient preference and diminish the market share of these existing therapies.

Global supply chain disruptions or raw material shortages might cause hydroxychloroquine and chloroquine to be in short supply at times. These supply chain flaws might jeopardize market stability and limit patient access to critical pharmaceuticals. Public health initiatives that prioritize mosquito control and preventive measures such as insecticide-treated bed nets are effective at reducing malaria transmission. If these preventive efforts are successful, they may reduce the total demand for antimalarial medications, including hydroxychloroquine, over time.

The emergence and spread of drug-resistant malaria strains pose a substantial threat to the effectiveness of hydroxychloroquine and chloroquine. Increasing resistance could reduce the medications' usefulness in treating malaria, diminishing market demand, and forcing alternate therapeutic techniques. As safety studies and regulatory scrutiny evolve, hydroxychloroquine and chloroquine may face more limits or modified guidelines. Changes in regulatory frameworks can have an impact on market dynamics by altering prescribing practices and market access conditions.

Category-Wise Acumens

How Do the Therapeutic Advantages and Utilization in Hospital and Emergency Settings Contribute to the Growth of the Injectable Segment in the Hydroxychloroquine and Chloroquine Market?

The Injectable segment is showing substantial growth in the Hydroxychloroquine and Chloroquine Market and is expected to continue its growth throughout the forecast period. Injectable formulations of hydroxychloroquine and chloroquine provide significant therapeutic benefits. They have a faster onset of action than oral tablets, making them ideal for emergency medical circumstances where immediate treatment is required. These injectables are especially popular in hospitals and emergency rooms, where accurate dose and speedy administration are critical for addressing severe instances of malaria, autoimmune illnesses such as lupus, and probable COVID-19 problems. Injectable versions are widely used in clinical trials and research studies to investigate new indications and treatment strategies. Their usage in research helps to advance the understanding and application of these medications in a variety of therapeutic areas.

For patients who have difficulty swallowing or who require constant medication consumption, injectables are a dependable option that ensures adherence to specified treatment regimens. Technological improvements in injectable drug delivery methods, such as sustained-release formulations and enhanced bioavailability, increase therapeutic outcomes and patient comfort, propelling the market forward. During global health crises such as the COVID-19 pandemic, injectable forms of hydroxychloroquine and chloroquine have seen increased demand due to their ability to provide immediate therapeutic intervention in severe cases and clinical trials investigating their effectiveness against viral infections.

Increasing regulatory approvals for injectable formulations across regions allows for more market access. Regulatory approval validates safety, efficacy, and quality standards, instilling confidence in both healthcare providers and patients. Healthcare professionals frequently prefer injectable formulations because they allow for accurate dosage administration and control, reducing the hazards associated with differences in oral absorption and patient compliance concerns. Injectable hydroxychloroquine and chloroquine meet special medical needs, such as intravenous injection during critical care, highlighting their importance in therapeutic regimens for complex illnesses.

How Do the Pandemic Response and Global Interest Contribute to the Expansion of the COVID-19 Segment in the Hydroxychloroquine and Chloroquine Market?

The COVID-19 segment is showing substantial growth in the Hydroxychloroquine and Chloroquine Market and is expected to continue its growth throughout the forecast period. Pandemic Response and Global Interest, the COVID-19 pandemic prompted global interest in hydroxychloroquine and chloroquine as potential remedies, with early observational studies indicating antiviral effectiveness against SARS-CoV-2, resulting in extraordinary demand. Emergency Use Authorizations (EUAs), many nations quickly approved EUAs for hydroxychloroquine and chloroquine to treat COVID-19 patients, resulting in an increase in prescriptions and market expansion to satisfy critical healthcare demands. Clinical Studies and Research Expansion, extensive clinical studies were launched around the world to evaluate the medications' efficacy against COVID-19, with significant research investment increasing the database and informing treatment methods.

Extensive media coverage raised public awareness and affected healthcare providers' prescribing patterns, boosting market demand despite ongoing arguments regarding efficacy and safety. Initially, global shortages and supply chain disruptions occurred as countries fought for hydroxychloroquine and chloroquine stockpiles, affecting distribution and availability. Regulatory Guidance and Adjustments, regulatory authorities such as the FDA and EMA provided developing guidance and warnings that influenced market access and utilization patterns in response to growing clinical evidence and safety concerns.

Hydroxychloroquine and chloroquine have been integrated into a variety of COVID-19 therapy protocols, including early intervention techniques and combination medications, broadening their clinical application. Impact on Concurrent Conditions, patients with autoimmune disorders such as RA and JIA had difficulty acquiring hydroxychloroquine due to diverted supply and increased demand during the pandemic, impacting treatment continuity. Long-term market Prospects, despite diverse trial results, continuous study and preparation for future pandemics maintain interest in hydroxychloroquine and chloroquine, shaping market dynamics beyond the immediate crisis response.

Country/Region-wise Acumens

How Do Market Size and Economic Influence, Along with Advanced Healthcare Infrastructure, Drive the Growth of the Hydroxychloroquine and Chloroquine Market in North America?

North America is estimated to dominate the Hydroxychloroquine and Chloroquine Market during the forecast period. North America, notably the United States, has a significant share of the worldwide pharmaceutical market, which includes hydroxychloroquine and chloroquine. The region's economic strength and healthcare spending contribute to its leading position. North America's advanced healthcare facilities and rigorous regulatory frameworks, such as the FDA, ensure widespread availability and stringent quality control of pharmaceutical items, including antimalarial and autoimmune disease treatments. North America has a substantial burden of autoimmune disorders such as rheumatoid arthritis and lupus, which fuels ongoing demand for hydroxychloroquine and chloroquine as viable therapeutic choices. Major pharmaceutical corporations and major research institutions in the United States perform substantial clinical trials and investigations on the efficacy and safety of hydroxychloroquine and chloroquine. This promotes innovation and strengthens the region's commercial position.

Government Policies and Healthcare Spending, favorable government policies, significant healthcare expenditure, and widespread insurance coverage allow broad access to hydroxychloroquine and chloroquine therapies, promoting their widespread use throughout North America. The use of modern drug delivery technologies and diagnostic methods improves the treatment of diseases treated with hydroxychloroquine and chloroquine, cementing the region's leadership in healthcare innovation. The COVID-19 pandemic resulted in an initial rise in demand for hydroxychloroquine in North America, spurred by preliminary hypotheses and clinical trials investigating its potential as a virus treatment. This increased interest affected market dynamics and use patterns. Intense competition among pharmaceutical companies and research institutions in North America drives ongoing product development and innovation, leading to the hydroxychloroquine and chloroquine market's rapid rise. Patient Awareness and Advocacy, high levels of patient awareness about treatment alternatives, together with strong advocacy groups advocating for increased drug access, contribute considerably to North America's sustained market growth and adoption rates.

North America has a concentration of clinical experience and a robust clinical trial infrastructure, which hastens the development and implementation of hydroxychloroquine and chloroquine treatments. Comprehensive insurance coverage and affordability schemes in North America ensure that patients have access to hydroxychloroquine and chloroquine, which supports long-term market growth. Well-established patient compliance programs and healthcare provider networks help patients adhere to hydroxychloroquine and chloroquine regimens, which helps to maintain market stability. Collaborations among pharmaceutical corporations, research institutes, and healthcare providers promote innovation and market penetration of hydroxychloroquine and chloroquine medicines.

How Do Rising Healthcare Expenditure and a Large Population Base in the Asia Pacific Region Propel the Rapid Expansion of the Hydroxychloroquine and Chloroquine Market?

The Asia Pacific region is estimated to exhibit the highest growth within the Hydroxychloroquine and Chloroquine Market during the forecast period. Countries such as China, India, and Japan are seeing significant increases in healthcare spending, which is driving strong development in the market for hydroxychloroquine and chloroquine. Asia Pacific's enormous and diversified population provides a significant patient pool for autoimmune disorders and malaria, resulting in high demand for hydroxychloroquine and chloroquine therapies. The high prevalence of malaria in Southeast Asia drives demand for antimalarial medications such as chloroquine, contributing to the region's strong growth in this market. Rapid economic growth in Asia Pacific's emerging markets is boosting healthcare facilities and increasing access to pharmaceutical therapies such as hydroxychloroquine and chloroquine. In Asia Pacific regions, cultural acceptance of Western medical methods and treatments effects hydroxychloroquine and chloroquine therapy uptake and demand.

Government activities aimed at improving healthcare access and controlling infectious diseases are critical to developing the market for hydroxychloroquine and chloroquine in the Asia Pacific. Increased investments in clinical research and trials are improving the understanding and application of hydroxychloroquine and chloroquine across a wide range of patient populations in Asia Pacific, fueling market growth. Ongoing regulatory changes and harmonization initiatives in the Asia Pacific are expediting drug approval and market entry processes, paving the way for market development. The growing acceptance of Western medical practices and treatments is driving up demand for hydroxychloroquine and chloroquine across the Asia Pacific, notably for autoimmune disorders. Initiatives to improve healthcare access and equity in Asia Pacific's rural and underserved areas increase the availability and use of hydroxychloroquine and chloroquine. As the population ages, countries such as Japan and South Korea see an increase in demand for age-related therapies such as hydroxychloroquine and chloroquine.

The rapid adoption of digital health technology and telemedicine platforms in the Asia Pacific improves healthcare delivery and access to hydroxychloroquine and chloroquine therapies. Differences in illness incidence throughout Asia Pacific areas influence demand dynamics for hydroxychloroquine and chloroquine, which are tailored to distinct local healthcare needs. Continued investment in healthcare infrastructure development in Asia Pacific countries broadens the scope and accessibility of hydroxychloroquine and chloroquine therapies. Government-led public health activities aimed at malaria prevention and control help to sustain demand for chloroquine in certain parts of Asia Pacific. Cross-border healthcare cooperation and regional partnerships help to exchange knowledge and create capacity for hydroxychloroquine and chloroquine management. Improved epidemiological surveillance and data analytics skills in Asia Pacific help to inform targeted treatments and chloroquine use plans.

Competitive Landscape

The Hydroxychloroquine and Chloroquine industry is highly competitive, with significant pharmaceutical companies vying for market share and innovation. Major firms including Novartis AG, Sanofi, and Mylan N.V. dominate the industry because to their extensive product portfolios and global distribution networks. These firms prioritize ongoing research and development to improve therapeutic efficacy and safety profiles, while also meeting severe regulatory standards. Strategic collaborations, mergers, and acquisitions are frequent strategies for strengthening market position and expanding geographical reach. Furthermore, the market is seeing continuing patent expirations and generic competition, which influence pricing dynamics and market accessibility for these critical treatments.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the hydroxychloroquine and chloroquine market include:

• Sanofi
• Zydus Cadila
• Ipca Laboratories Ltd
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Lupin Limited
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Hydroxychloroquine and Chloroquine Market Latest Developments:
• In June 2021, Catalent, Inc announced that they will acquire Rhein Cell Therapeutics GmbH, a leading developer and manufacturer of GMP-grade human induced pluripotent stem cells. This acquisition will help the company's existing stem cell therapy process development and manufacturing capabilities.
• In December 2020, Lonza announced that they have expanded their collaboration with Aurinia Pharmaceuticals to expand a manufacturing capacity for efficient production and manufacturing of Voclosporin
• In July 2020, the USFDA cautioned against the use of hydroxychloroquine and chloroquine to treat hospitalized COVID-19 patients with COVID-19 due to the risk of heart rhythm problems, blood and lymph system disorders, kidney injuries, and liver problems and failure

Hydroxychloroquine and Chloroquine Market, By Category

• Type:
• Oral Tablets
• Injectable
• Application:
• COVID-19
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Malaria
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HYDROXYCHLOROQUINE AND CHLOROQUINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HYDROXYCHLOROQUINE AND CHLOROQUINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HYDROXYCHLOROQUINE AND CHLOROQUINE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Oral Tablets
• 5.3 Injectable

6 GLOBAL HYDROXYCHLOROQUINE AND CHLOROQUINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 COVID19
• 6.3 Juvenile Idiopathic Arthritis
• 6.4 Rheumatoid Arthritis
• 6.5 Malaria
• 6.6 Others

7 GLOBAL HYDROXYCHLOROQUINE AND CHLOROQUINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL HYDROXYCHLOROQUINE AND CHLOROQUINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Ipca Laboratories
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Zydus Cadila
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Sanofi S.A.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 McW Healthcare
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Macleods Pharmaceuticals Ltd
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Cipla Limited
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Lupin Limited
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Mylan N.V.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Abbott India Ltd
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 10.1 Related Research